Patrick Daly

DocwireNews

Researchers reported that deferiprone safety and efficacy was comparable with deferoxamine for treating iron overload in pediatric patients, according to a post hoc analysis published in Pediatric Blood &amp; Cancer.Researchers compared the safety and efficacy of deferiprone and deferoxamine in patients aged 17 years or younger with sickle cell disease or other anemias who participated in the phase IIIb/IV FIRST trial. Deferoxamine is injected subcutaneously while deferiprone is an oral agent.Children who receive frequent blood transfusions to manage <a href="https://www.docwirenews.com/page/heme-today">sickle cell disease</a> often require iron chelation therapy to reduce iron overload. The researchers suggested that &ldquo;deferiprone is an oral chelation option that could improve adherence and outcomes in children.&rdquo;<h2>Deferiprone Outcomes Consistent with Deferoxamine in Pediatric SCD</h2>The analysis included 142 pediatric patients who were treated with deferiprone or deferoxamine in <a href="https://clinicaltrials.gov/study/NCT02041299">FIRST</a>. The deferiprone group had a mean age of 10.5 years and the deferoxamine group had a mean age of 11.7 years. After 12 months of treatment, the mean change from baseline in liver iron concentration (LIC) in the deferiprone group was -3.3 mg/g dry weight compared with -3.4 mg/g dry weight in the deferoxamine group (P=.8216).Magnetic resonance imaging data showed the relative mean change in log cardiac T2* was 1.02 (coefficient of variation, 21.8%) with deferiprone versus 0.95 (coefficient of variation, 19.5%) with deferoxamine (P=.0717). Additionally, the mean changes in serum ferritin levels were -133.0 &mu;g/L (standard error, 200.3) and -467.1 &mu;g/L (standard error, 244.1) with deferiprone and deferoxamine, respectively.Adverse events related to deferiprone were most commonly upper abdominal pain (20.2%), vomiting (13.8%), pyrexia (9.6%), increased alanine aminotransferase (9.6%), increased aspartate aminotransferase (9.6%), and decreased neutrophil count (9.6%). The authors noted most neutrophil, aspartate aminotransferase, and alanine aminotransferase changes were resolved without intervention.Overall, the authors of the analysis concluded that &ldquo;this post hoc subgroup analysis of pediatric patients receiving chronic transfusions for [sickle cell disease] or other anemias corroborated previous findings that deferiprone is comparable to deferoxamine in reducing [liver iron concentration].&rdquo;ReferenceHamdy M, El-Beshlawy A, Ver&iacute;ssimo MPA, et al. Deferiprone versus deferoxamine for transfusional iron overload in sickle cell disease and other anemias: pediatric subgroup analysis of the randomized, open-label FIRST study.&nbsp;Pediatr Blood Cancer. 2023;e30711. doi:10.1002/pbc.30711Related: <a href="https://www.docwirenews.com/post/characterizing-infections-in-children-with-sickle-cell-disease-over-time">Characterizing Infections in Children With Sickle Cell Disease Over Time</a>

Jordana Jampel

Brensocatib Shows Positive Results for Managing Bronchiectasis Symptoms

Pulmonology

Areef Ishani, MD

Joel M. Topf, MD, FACP

Kidney Stones With Chlorthalidone Versus Hydrochlorothiazide

NKF Spring Clinical Meetings 2025

MarkAlain Déry, DO

Eric Griggs, MD

Measles in America: An Ongoing Problem

Infectious Disease

Latest News

Deferiprone Is Comparable With Deferoxamine in Pediatric Sickle Cell Disease

Sickle Cell Disease

Oral deferiprone achieved safety and efficacy outcomes comparable with subcutaneous deferoxamine for pediatric patients with sickle cell disease.

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe